Elanco Animal Health announced a $130 million, 25,000-square-foot expansion of its biologics manufacturing facility in Elwood, Kansas, expected to be completed by 2026. The expansion aims to further develop Elanco’s monoclonal antibody (mAb) platform, enhancing its existing capabilities.

This facility currently produces Canine Parvovirus Monoclonal Antibody (CPMA), the only USDA-approved treatment for canine parvovirus, a disease affecting over 330,000 puppies annually. Elanco plans to introduce a new mAb product for canine dermatology by 2025.

The investment will double production capacity, add a pilot plant to accelerate product pipeline development, and include a new quality control laboratory. Grace McArdle, Executive Vice President of Manufacturing and Quality, emphasized the facility’s critical role in advancing Elanco’s R&D efforts and transforming animal care. Elanco views monoclonal antibodies as key to future innovations in pet health, with the potential to improve clinical outcomes and strengthen the human-animal bond. Design-build firm Burns & McDonnell will oversee the project’s construction and design.